Margaret Porter Scott

7.5k citations

34 papers · 3.5k indexed · 3 hit papers · h-index 23

Molecular Biology top 2%
- Epigenetics and DNA Methylation 22
- Cancer-related gene regulation 21
- RNA modifications and cancer 10
- Protein Kinase Regulation and GTPase Signaling 3
Hematology top 5%
- Acute Myeloid Leukemia Research 5
Genetics top 5%
Cancer Research top 10%
Oncology top 10%
Pulmonary and Respiratory Medicine
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 2
Spectroscopy
- Analytical Chemistry and Chromatography 2
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 2

Co-authors: Robert A. Copeland Victoria M. Richon Roy M. Pollock Kevin W. Kuntz Mikel P. Moyer Sarah K. Knutson Richard Chesworth W. Todd Miller
Cited by: Molecular Biology Hematology Genetics
Journals: Proceedings of the National Academy of Sciences (2 papers)Journal of the American Chemical Society (1 paper)Journal of Biological Chemistry (1 paper)
Partner nations: United States United Kingdom Japan

In The Last Decade

Margaret Porter Scott

33 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2013 Proceedings of the National Academy of Sciences
2013 Blood
2010 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Margaret Porter Scott

Since Specialization

Citations

This map shows the geographic impact of Margaret Porter Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret Porter Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret Porter Scott more than expected).

Fields of papers citing papers by Margaret Porter Scott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret Porter Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret Porter Scott. The network helps show where Margaret Porter Scott may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Margaret Porter Scott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Margaret Porter Scott Line = papers co-authored together Margaret Porter Scott links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Identification of a peptide inhibitor for the histone methyltransferase WHSC1 PLoS ONE ·Michael J. Morrison,P. Ann Boriack‐Sjodin,Kerren K. Swinger,Tim J. Wigle,Dipti Sadalge,Kevin W. Kuntz,Margaret Porter Scott,William P. Janzen,Richard Chesworth,Kenneth W. Duncan,Darren M. Harvey,John W. Lampe,Lorna H. Mitchell,Robert A. Copeland	2018	22
2	A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening SLAS DISCOVERY ·Tim J. Wigle,Kerren K. Swinger,John E. Campbell,Michael D. Scholle,John Sherrill,Elizabeth A. Admirand,P. Ann Boriack‐Sjodin,Kevin W. Kuntz,Richard Chesworth,Mikel P. Moyer,Margaret Porter Scott,Robert A. Copeland	2015	31
3	Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666 ACS Medicinal Chemistry Letters ·Kenneth W. Duncan,Nathalie Rioux,P. Ann Boriack‐Sjodin,Michael J. Munchhof,Lawrence A. Reiter,Christina R. Majer,Lei Jin,L. Danielle Johnston,Elayne Chan-Penebre,Kristy G. Kuplast,Margaret Porter Scott,Roy M. Pollock,Nigel J. Waters,J. Joshua Smith,Mikel P. Moyer,Robert A. Copeland,Richard Chesworth	2015	103
4	EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity ACS Medicinal Chemistry Letters ·John E. Campbell,Kevin W. Kuntz,Sarah K. Knutson,Natalie M. Warholic,Heike Keilhack,Tim J. Wigle,Alejandra Raimondi,Christine R. Klaus,Nathalie Rioux,Akira Yokoi,Satoshi Kawano,Yukinori Minoshima,Hyeong-Wook Choi,Margaret Porter Scott,Nigel J. Waters,J. Joshua Smith,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland	2015	94
5	DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells Journal of Pharmacology and Experimental Therapeutics ·Christine R. Klaus,Dorothy Iwanowicz,Danielle Johnston,Carly A. Campbell,J. Joshua Smith,Mikel P. Moyer,Robert A. Copeland,Edward J. Olhava,Margaret Porter Scott,Roy M. Pollock,Scott R. Daigle,Alejandra Raimondi	2014	96
6	Potent inhibition of DOT1L as treatment of MLL-fusion leukemiabreakdown → Blood ·Scott R. Daigle,Edward J. Olhava,Carly A. Therkelsen,Aravind Basavapathruni,Lei Jin,P. Ann Boriack‐Sjodin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,Nigel J. Waters,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland,Victoria M. Richon,Roy M. Pollock	2013	546
7	Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys27 methylation by human polycomb repressive complex 2 and vSET Biochemical Journal ·Brooke M. Swalm,Kenneth K. Hallenbeck,Christina R. Majer,Lei Jin,Margaret Porter Scott,Mikel P. Moyer,Robert A. Copeland,Tim J. Wigle	2013	5
8	EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models Blood ·L. Danielle Johnston,Sarah K. Knutson,Natalie M. Warholic,Christine R. Klaus,Tim J. Wigle,Dorothy Iwanowicz,Bruce A. Littlefield,Margaret Porter Scott,J. Joshua Smith,Mikel P. Moyer,Robert A. Copeland,Roy M. Pollock,Kevin W. Kuntz,Heike Keilhack,Alejandra Raimondi	2013	5
9	A pathway from leukaemogenic oncogenes and stem cell chemokines to RNA processing via THOC5. Accepted September 2012. Research Explorer (The University of Manchester) ·François Griaud,Andrew Pierce,María B. Sánchez,Margaret Porter Scott,Sheela A. Abraham,Tessa L. Holyoake,Damian Tran,Teruko Tamura,Anthony D. Whetton	2012	1
10	A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients FEBS Letters ·Christina R. Majer,Lei Jin,Margaret Porter Scott,Sarah K. Knutson,Kevin W. Kuntz,Heike Keilhack,J. Joshua Smith,Mikel P. Moyer,Victoria M. Richon,Robert A. Copeland,Tim J. Wigle	2012	116
11	Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L Chemical Biology & Drug Design ·Aravind Basavapathruni,Lei Jin,Scott R. Daigle,Christina R. Majer,Carly A. Therkelsen,Tim J. Wigle,Kevin W. Kuntz,Richard Chesworth,Roy M. Pollock,Margaret Porter Scott,Mikel P. Moyer,Victoria M. Richon,Robert A. Copeland,Edward J. Olhava	2012	114
12	Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL-Rearranged Leukemia. Blood ·Roy M. Pollock,Scott R. Daigle,Carly A. Therkelsen,Aravind Basavapathruni,Lei Jin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland,Victoria M. Richon,Edward J. Olhava	2012	3
13	Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis Analytical Biochemistry ·Robert A. Copeland,Aravind Basavapathruni,Mikel P. Moyer,Margaret Porter Scott	2011	82
14	Chemogenetic Analysis of Human Protein Methyltransferases Chemical Biology & Drug Design ·Victoria M. Richon,Danielle Johnston,Christopher J. Sneeringer,Lei Jin,Christina R. Majer,Keith Elliston,L. Fred Jerva,Margaret Porter Scott,Robert A. Copeland	2011	151
15	The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states FEBS Letters ·Tim J. Wigle,Sarah K. Knutson,Lei Jin,Kevin W. Kuntz,Roy M. Pollock,Victoria M. Richon,Robert A. Copeland,Margaret Porter Scott	2011	62
16	Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomasbreakdown → Proceedings of the National Academy of Sciences ·Christopher J. Sneeringer,Margaret Porter Scott,Kevin W. Kuntz,Sarah K. Knutson,Roy M. Pollock,Victoria M. Richon,Robert A. Copeland	2010	500
17	Targeting epigenetic enzymes for drug discovery Current Opinion in Chemical Biology ·Robert A. Copeland,Edward J. Olhava,Margaret Porter Scott	2010	87
18	Identification of Novel SH3 Domain Ligands for the Src Family Kinase Hck Journal of Biological Chemistry ·Margaret Porter Scott,Francesca Zappacosta,Eun Young Kim,Roland S. Annan,W. Todd Miller	2002	63
19	Progesterone Receptor Contains a Proline-Rich Motif that Directly Interacts with SH3 Domains and Activates c-Src Family Tyrosine Kinases Molecular Cell ·Viroj Boonyaratanakornkit,Margaret Porter Scott,Vered Ribon,Lori Sherman,Steven M. Anderson,James L. Maller,W. Todd Miller,Dean P. Edwards	2001	480
20	Sequential immunological studies in an asbestos-exposed population. II. Factors affecting lymphocyte function. PubMed ·Mark J. Campbell,M M Wagner,Margaret Porter Scott,D G Brown	1980	26

About Margaret Porter Scott

Margaret Porter Scott is a scholar working on Molecular Biology, Hematology and Pharmaceutical Science, having authored 34 papers that have together received 3.5k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (22 papers), Cancer-related gene regulation (21 papers), RNA modifications and cancer (10 papers), Acute Myeloid Leukemia Research (5 papers), Protein Kinase Regulation and GTPase Signaling (3 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers), Analytical Chemistry and Chromatography (2 papers) and Acute Lymphoblastic Leukemia research (2 papers). The work is most often cited by research in Molecular Biology (2.9k citations), Hematology (335 citations) and Genetics (473 citations). Margaret Porter Scott has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Robert A. Copeland, Victoria M. Richon, Roy M. Pollock, Kevin W. Kuntz, Mikel P. Moyer, Sarah K. Knutson, Richard Chesworth, W. Todd Miller, Lei Jin and Alejandra Raimondi. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact